Two years ago, a gene therapy restored hearing to a small group of children who had been born deaf, and some of them heard for the first time, indistinct murmurs resolving into audible whispers. The strength of those results, and the absence of safety problems, led the Food and Drug Administration to approve Regeneron's Otarmeni this past April for the small group of people with the rare genetic mutation it targets. Now a wave of startups, in the United States, France, and China, is racing toward other genetic causes of deafness, with Skylark Bio emerging from stealth this week to announce it had dosed its first patient with a therapy aimed at a child who carries a different mutation.
The science is genuinely remarkable, and moving quickly. But it is arriving into a conversation more complicated than the triumphant framing of the headlines suggests, and how these therapies are offered may end up mattering as much as whether they work.
Why one mutation came first
The first success was not a matter of which genetic cause of deafness is most common. It was a matter of which is easiest to fix. The approved therapy targets mutations in a gene called otoferlin, and those mutations have an unusual and convenient property: they leave the structure of the ear completely intact. The delicate hair cells and the auditory neurons are all present and healthy, and the only thing missing is a single protein needed to pass the signal along.
That makes otoferlin, as former Decibel Therapeutics researcher Joe Burns described it, a "Goldilocks" target, one where the ear stays intact in animal models even into old age. Because the hardware is whole, restoring the missing gene amounts to something close to a software fix: supply the absent protein, and the intact machinery starts working. That is why a rare mutation, rather than a common one, became the proving ground. It was simply the most tractable place to show the approach could work.
The race for the "holy grail"
The bigger prize is a gene called GJB2, the single most common cause of inherited deafness, which is why researchers describe it as the holy grail and why startups across three countries are now competing to reach it first. It is also a harder target, and the field that has formed around it, American, French, and Chinese biotechs each pursuing different mutations, reflects both the scale of the opportunity and the difficulty of the problem.
Skylark Bio's arrival, with a first patient already dosed, is one entry in what has suddenly become a crowded race. The trajectory is clear enough: from the most tractable mutation toward the most common one, gene therapy for deafness is advancing fast, and more approvals of some kind seem likely in the years ahead. On the science alone, this is one of the more striking stories in medicine right now.
"Restoring hearing" is not a simple, universal good
Here the story becomes more complicated than a straightforward account of medical progress. The natural way to tell it is as a triumph, children hearing for the first time, medicine overcoming deafness, and for many families that is precisely the reality they hoped for. Their joy is real, and it deserves no asterisk. A parent who has longed for their child to hear, or a deaf adult who wants to hear, is not making a mistake.
But that framing collides with a deeply held and entirely legitimate perspective within much of the Deaf community: that deafness is not a defect or a disease but a difference, the foundation of a rich linguistic and cultural world with its own languages, history, art, and identity. To describe it as something to be cured carries, for many Deaf people, a troubling implication, that people like them are a problem to be solved, ideally out of existence. The same therapy can be, to one family, a longed-for miracle, and to another person, a technology built on the premise that they should not exist. Both of those responses are sincere, and both are grounded in real experience.
Both perspectives are legitimate
The temptation is to resolve this tension by deciding which side is right. The more honest move is to recognize that both are. The family choosing the therapy is making a loving, legitimate, deeply personal decision, and the treatment genuinely expands the options available to them; to dismiss that choice as a betrayal of Deaf culture would deny individuals the right to decide for themselves and their children. Autonomy cuts in favor of access.
And the Deaf-community perspective is equally legitimate. Deaf culture is real and self-sustaining, sign languages are complete natural languages by every linguistic measure, and Deaf identity is a source of belonging and pride rather than of deprivation. The wariness toward a "cure" is also well-earned, given a long history in which deaf people were fixed against their will, forbidden to sign, forced to lip-read, and treated as broken by a medical establishment that overlooked their full humanity. That history is not a footnote; it is the reason the framing of these therapies is watched so closely. Neither of these perspectives cancels the other out, and a discussion that erases either one is poorer for it.
The distinction that actually matters
The way to hold both at once is to separate the therapy from its framing, because that is where the real question lives. Offered as a choice, to families and to individuals who want it, the therapy is a genuine good, precisely because it widens the range of ways people can live as they wish. It becomes troubling only when the framing shifts from offering an option to pronouncing a defect, when the message changes from "here is a choice you may want" to "here is the correct repair for a flaw, and the flaw is you."
The technology can be wholeheartedly embraced by those who want it without anyone endorsing the premise that Deaf people are defective, or that a thriving culture is a condition in need of elimination. The good lies in the choosing. The harm, where there is any, lies in the verdict, the judgment that would strip away the choice, or look down on those who decline it, or quietly assume that the right number of deaf people in the world is zero. Keeping those two things distinct is most of what it takes to talk about this well.
The hardest case
The sharpest version of the tension is the one the current trials embody directly: therapies given to very young children who cannot consent, on the decision of their parents. For most parents, that is a loving choice made in what they sincerely believe is their child's best interest, and it is genuinely theirs to make. Parents make consequential, irreversible decisions for their children constantly, and this is, in one light, another of them.
It is also, in the view of some in the Deaf community, a choice imposed on a child who might otherwise have grown up inside Deaf culture and language, made before the child is old enough to weigh in on their own relationship to sound and silence. There is no clean resolution here. Both the parents' love and the community's concern are real, and the honest response is not to hand either an easy victory but to acknowledge the genuine weight of deciding so intimate a thing on another person's behalf before that person can speak to it. Sitting with that difficulty is more truthful than resolving it prematurely.
The science, to be clear, is remarkable, and the joy of a family whose child hears for the first time is real and complete on its own terms. But gene therapy for deafness is also, unavoidably, a story about how a society talks about difference, and the most respectful way to hold it is to keep the treatment and its framing apart. A therapy that gives people a choice they want is a good thing, and it can be exactly that without carrying any message that Deaf lives are lesser, or that a rich culture is a problem awaiting a solution. The aim worth keeping is not a world with fewer deaf people in it. It is a world in which deaf people and their families have more choices, to embrace Deaf identity, to pursue hearing, to do both in their own way and their own time, and in which none of those choices is treated as the obvious or the only correct one. The technology is arriving quickly. The wisdom is in offering it as an option, and not delivering it as a verdict.
Primary sources
- STAT, in reporting by O. Rose Broderick, for Skylark Bio's emergence from stealth and the dosing of its first patient with a therapy targeting a GJB2 mutation, the framing of GJB2 as the "holy grail" and most common genetic cause of deafness, the race among startups in the United States, France, and China pursuing different mutations, the FDA's April approval of Regeneron's Otarmeni for otoferlin-related mutations, the account of the 2024 trial that restored hearing to children born deaf, and Joe Burns's description of otoferlin as a "Goldilocks" target whose intact ear structure persists even in aged animal models.
- The FDA for the approval of the first gene therapy for a genetic form of hearing loss.
- STAT's earlier 2024 reporting for the history-making gene-therapy results and for the Deaf community's concerns about such therapies.
- General, well-established background on the biology of otoferlin and GJB2, on Deaf culture and sign languages as full natural languages, on the history of oralism and the medical "fixing" of deaf people, and on the long-running debates over cochlear implants and Deaf identity.